Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development
Agency: National Institutes of Health
- 93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders
Forecasted opportunityLast Updated: Jul 7, 2026
Important dates
- Forecasted post date: November 15, 2026
- Forecasted application due date: June 16, 2027
- Forecasted award date: March 5, 2028
- Forecasted project start date: April 1, 2028
- Fiscal Year: 2028
Award details
- Expected project funding: Not specified
- Expected awards: 4
Award min.
Not specified
Award max.
Not specified
- Funding opportunity number:PAR-28-043
- Cost sharing or matching requirement:No
- Funding instrument type:
- Cooperative agreement
- Opportunity Category:Discretionary
- Opportunity Category Explanation:Not specified
- Category of Funding Activity:
- Health
- Category Explanation:Not specified
History
- Forecast posted date: July 7, 2026
- Archive date: Not specified
- Version: 1
Summary
The NIH Blueprint for Neuroscience Research is interested in continuing to support the BluePrint Neurotherapeutics Network for Small Molecules (BPN-SM)- a program designed to help investigators advance promising small-molecule therapeutics toward clinical testing. The BPN-SM program supports drug discovery and development activities in investigators’ own laboratories while also providing access to NIH-supported subject matter experts and contract research organizations (CROs) with capabilities in medicinal chemistry, pharmacokinetics, toxicology, formulation development, GMP synthesis, and Phase I clinical testing. By integrating NIH resources with industry-standard expertise, BPN-SM advances investigator-initiated drug discovery while enabling investigators to retain and strengthen their intellectual property while gaining hands-on experience in translational drug development.
The overarching goal of the program is to reduce the risk of scientific and therapy development sufficiently to enable external partners to take on late-stage development and ultimately bring new therapies to patients. In addition, this BPN program is specifically focused on small molecules and excludes biologics, because development, regulatory, and manufacturing considerations for each class of therapeutics differ substantially from each other. It will use a phased cooperative agreement mechanism which will enable the program to support innovative but higher-risk projects, with decisions of continued support being contingent on demonstrated feasibility of yearly milestones. A cooperative agreement framework is proposed because several key aspects of the program will involve collaborative activities between the investigators and NIH program staff, with substantial involvement beyond the normal scope of grant stewardship. The project principal investigator(s) and NIH program staff will work jointly with NIH-supported subject matter experts to coordinate and participate in all scientific and technical management aspects of the project.
Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop competitive projects and establish the cross-disciplinary collaborations necessary for success.
Eligibility
Government
- County governments
- State governments
- City or township governments
- Public and Indian housing authorities
- Special district governments
- Federally recognized Native American tribal governments
Nonprofit
- Nonprofits non-higher education with 501(c)(3)
- Other Native American tribal organizations
- Nonprofits non-higher education without 501(c)(3)
Business
- Small businesses
- For-profit organizations other than small businesses
Education
- Private institutions of higher education
- Public and state institutions of higher education
- Independent school districts
Miscellaneous
- Other
Additional information on eligibility
Documents
No documents are currently available.
Agency contact information
Email: BPNSMNINDS@mail.nih.gov
BPNSMNINDS@mail.nih.gov
Link to additional information
No additional information is available
